Replies to post #39166 on Propanc Biopharma Inc (PPCB)

[krisc62]

Just FYI,
“PPCB began the year 2018 repaying $4.2 million of the $4.7 million in senior secured debt originally borrowed from Magna Invests. In our opinion, the repayment of debt is quite positive and will help the company raise capital for the First-In-Human study in 2018.”

Plus according to article on 3/23/18:

“GBI Research, the company is targeting a market segment of $14 billion in 2020. If PPCB is able to grab a small amount of that market, we will be expecting the share price to rebound seriously. In our opinion, seeing the first revenues will take time, as the company will need to work with the FDA and the process is long. However, in 2018, we will receive the data from the First-In-Human study, and it could make the share price run.”